Immunocore (NasdaqGS:IMCR) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBahija Jallal - CEOGraig Suvannavejh - Managing DirectorMohammed Dar - EVP of Clinical Development and Chief Medical OfficerMorgan Morse - Investor Relations ManagerPaul Jeng - VP of Biotechnology Equity ResearchRajan Sharma - Pharma and Biotech Equity ResearchRalph Torbay - EVP of CommercialSean Laaman - Executive DirectorTravis Coy - CFO and Head of Corporate DevelopmentConference Call ParticipantsEric Schmi ...

Immunocore (NasdaqGS:IMCR) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBahija Jallal - CEOGraig Suvannavejh - Managing DirectorMohammed Dar - EVP of Clinical Development and Chief Medical OfficerMorgan Morse - Investor Relations ManagerPaul Jeng - VP of Biotechnology Equity ResearchRajan Sharma - Pharma and Biotech Equity ResearchRalph Torbay - EVP of CommercialSean Laaman - Executive DirectorTravis Coy - CFO and Head of Corporate DevelopmentConference Call ParticipantsEric Schmi ...

Immunocore (NasdaqGS:IMCR) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker8note that this conference is being recorded. I will now turn the conference over to Morgan Morse, Investor Relations. Thank you, Morgan. You may begin.Speaker7Thank you, Daryl. Good morning and good afternoon. Thank you for joining us on our Q4 and full year 2025 earnings call. During today's call, we will make some forward-looking statements which are qualified by our safe harbor provision under the Private Securities Li ...

4Q & FY 2025 Financial Results & Business Update To add/change the picture: Transformative immunomodulating medicines for patients • Click on the image and press BACKSPACE or DELETE on the keyboard > Click on the icon at the centre of the placeholder > Select the chosen image • To adjust the crop, right-click on the image > Crop • If for any reason the image placeholder loses the rounded shape, click on Reset button in the Home tab at the top. To add/change the picture: • Click on the image and press BACKSP ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ________ to ________ Commission File Number 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) (State or other jurisdi ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional ...

Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report finan ...

Immunocore Holdings PLC Sponsored ADR (IMCR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tra ...

Company Overview - Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company focused on developing TCR bispecific immunotherapies for cancer, infectious diseases, and autoimmune conditions, utilizing its proprietary ImmTAX technology [4] Investment Potential - Analysts from H.C. Wainwright and UBS have reiterated a Buy rating for Immunocore, with price targets of $100 and $55 respectively, indicating strong confidence in the stock's future performance [1][2] - UBS highlights significant upside potential for the stock, as it is currently trading near the value of its approved drug Kimmtrak, suggesting that the market has not fully valued the company's upcoming phase 3 trials [2] Upcoming Trials - The company has two key upcoming trials: the TEBE-AM trial for second-line Kimmtrak in metastatic cutaneous melanoma, with data expected by late 2026 or early 2027, and the first-line PRAME trial, with data anticipated in late 2027 or 2028 [3] Market Impact - Positive results from the upcoming trials could potentially boost the stock by 25% to 50% and contribute an additional $300 million to $400 million in annual sales [2]

Core Insights - Immunocore Holdings plc announces the departure of Dr. David Berman, Executive Vice President of Research and Development, effective February 27, 2026, as he takes a new role at another biotech company [1] - The company will not seek a direct replacement for Dr. Berman but will streamline its R&D structure, promoting Dr. Mohammed Dar and Mark Moyer to Executive Vice President roles [2] Leadership Changes - Dr. Mohammed Dar, previously Chief Medical Officer, has extensive experience in leading clinical development and will now oversee expanded clinical development and regulatory strategies [4] - Mark Moyer, who has been with Immunocore since 2018, will become EVP, Chief Regulatory and Quality Officer, having led the regulatory strategy for KIMMTRAK, which is now approved in 39 countries [5] Company Overview - Immunocore is a commercial-stage biotechnology company focused on developing TCR bispecific immunotherapies, particularly its lead product KIMMTRAK, which treats HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma [6]